The DOI matches its Crossref record.
Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue
Open accessAbstract
Dalbavancin is an intravenous lipoglycopeptide with activity against Gram-positive pathogens and an MIC 90 for Staphylococcus aureus of 0.06 μg/ml. With a terminal half-life of >14 days, dosing regimens with infrequent parenteral administration become available to treat infectious diseases such as osteomyelitis and endocarditis that otherwise require daily dosing for many weeks. In order to support a rationale for these novel regimens, the pharmacokinetics over an extended dosing interval and the distribution of dalbavancin into bone and articular tissue were studied in two phase I trials and pharmacokinetic modeling was performed. Intravenous administration of 1,000 mg of dalbavancin on day 1 followed by 500 mg weekly for seven additional weeks was well tolerated and did not demonstrate evidence of drug accumulation. In a separate study, dalbavancin concentrations in cortical bone 12 h after infusion of a single 1,000-mg intravenous infusion were 6.3 μg/g and 2 weeks later were 4.1 μg/g. A two-dose, once-weekly regimen that would provide tissue exposure over the dalbavancin MIC for Staphylococcus aureus for 8 weeks, maximizing the initial exposure to treatment while minimizing the frequency of intravenous therapy, is proposed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Staphylococcal Osteomyelitis: Disease Progression, Treatment Challenges, and Future Directions
Kavanagh, N., Ryan, E. J., Widaa, A., Sexton, G., Fennell, J., O'Rourke, S., Cahill, K. C., Kearney, C. J., O'Brien, F. J., & Kerrigan, S. W. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00084-17 · Cited by 547
Holland, T. L., Baddour, L. M., Bayer, A. S., Hoen, B., Miro, J. M., & Fowler, V. G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.59 · Cited by 406
Important new therapies for methicillin-resistant Staphylococcus aureus
Bassetti, M., Carnelutti, A., Castaldo, N., & Peghin, M. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1675637 · Cited by 21
Metadata
- Authors
- Dunne, M. W., Puttagunta, S., Sprenger, C. R., Rubino, C., Van Wart, S., & Baldassarre, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2015-04
- Volume
- 59
- Issue
- 4
- Pages
- 1849-1855
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2142067742
- Cited by
- 232
- References
- 0
- FWCI
- 7.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue. https://app.cochat.ai/papers/10.1128/aac.04550-14
- The paper
- Dunne, M. W., Puttagunta, S., Sprenger, C. R., Rubino, C., Van Wart, S., & Baldassarre, J. (2015). Extended-Duration Dosing and Distribution of Dalbavancin into Bone and Articular Tissue. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.04550-14
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.